Researchers at Turku Bioscience in joint collaboration with the Örebro University, Sweden have uncovered new ‘metabolic signatures’ of human CD4+ T-cells
From left to right: Dr. Alex M Dickens*, Dr. Partho Sen*, Dr. Syed Bilal Ahmad Andrabi+ and Dr. Tanja Buchacher+. ‘*’ represents Systems Medicine group headed by Prof. Matej Orešič, and ‘+’ represents Molecular Systems Immunology group headed by Prof. Riitta Lahesmaa.
T-cells are white blood cells that coordinate our immune response and provide protection against pathogens and cancer. Abnormally functioning T cells may lead to the development of cancer or autoimmune disorders.
Scientists at University of Turku and Örebro University studied metabolism of human T cells with sophisticated, cutting edge technologies such as computer-based modelling, high throughput lipidomics, transcriptomics techniques, and conducting in vitro knockdown experiments. They identified that certain molecular lipids such as ceramides and glycosphingolipids play an important role in the functioning of human T cells.
Intriguingly, these lipids were found to be regulated differently in T cell subsets. Experimental manipulation of glycosphingolipid pathways altered the T-cell functions. Particularly, the expression of proinflammatory cytokines was affected in a subset of T-cells called Th17 cells, known to be associated with various immune-mediated disease such as autoimmune diseases, and cancer. In particular, the study identified serine palmitoyl transferase (SPT), as an important target for regulating the expression of proinflammatory cytokine (IL17A and IL17F) by Th17 cells. The authors say “ Our results provide basis for engineering and manipulating metabolism of human T-cells to treat immune-mediated diseases”.
Manipulating human T-cell metabolism to modulate their early specification for therapeutic purposes is a new paradigm and offers significant new options in the future to develop safe and effective therapies for cancer and autoimmune diseases. Since ceramides are lipotoxic lipids that are commonly elevated in obesity and insulin resistance, our study may also offer clues about the poorly understood overlap in co-morbidities between specific immune-mediated diseases characterized by expression of proinflammatory cytokines and metabolic diseases, such as has been found to occur in COVID19.
Article published in Cell Reports, titled as “Quantitative genome-scale metabolic modeling of human CD4+ T-cell differentiation reveals subset-specific regulation of glycosphingolipid pathways”. Link to article
Recent Posts
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026
- Laura Elo is awarded the Leif C. Groop Award for outstanding research on type 1 diabetesLaura Elo a group leader at Turku Bioscience is awarded the Leif C. Groop Award Read moreFebruary 23, 2026